Table of Contents
- Clinical trial overview
- RP2 in advanced uveal melanoma
- Long-term safety follow-up after RP1, RP2, or RP3
- What the trials measure
- Who may take part
- Trial phases and study design
- Key terms explained
Clinical trial overview
The available studies of RP2 focus on two main goals: testing how well it works in advanced cancer and checking long-term safety after treatment.[1][2] One study looks at adults with advanced uveal melanoma, while the other follows patients who were previously treated with RP1, RP2, or RP3.[1][2]
RP2 in advanced uveal melanoma
NCT06581406 is an interventional, authorised Phase 4 study in 328 adult patients with metastatic uveal melanoma who have not previously been treated with immune checkpoint inhibitors.[1] The study compares RP2 plus nivolumab against ipilimumab plus nivolumab.[1]
The main goal is to compare overall survival, which means how long patients live after randomization, and progression-free survival, which means how long the cancer stays from getting worse or the patient dies.[1] The trial uses blinded independent central review, or BICR, and RECIST 1.1 to judge whether the disease has progressed.[1]
Long-term safety follow-up after RP1, RP2, or RP3
NCT06887348 is an authorised Phase 3 interventional study with 76 patients previously treated with RP1, RP2, or RP3.[2] It includes people with metastatic melanoma, advanced solid tumors, hepatocellular carcinoma, and melanoma.[2]
This study does not focus on short-term tumor response; instead, it looks at long-term safety and delayed adverse events that may appear later after treatment.[2] The study is designed to identify problems such as new malignancies, worsening neurologic disorders, worsening rheumatologic or other autoimmune disorders, new blood disorders, infections related to RPx, and herpetic infection with RPx detected in samples from herpetic lesions.[2]
What the trials measure
In the uveal melanoma study, the main outcomes are OS and PFS, which are standard ways to measure whether treatment helps patients live longer and keep their cancer under control for longer.[1] These outcomes are important because they show both survival benefit and disease control.[1]
In the safety study, the main outcome is the appearance of delayed adverse events, including new or worsening medical problems that may be linked to treatment with an RPx product.[2] This helps researchers understand whether any late safety issues occur after treatment has already ended.[2]
Who may take part
The Phase 4 RP2 study is for adult patients with advanced uveal melanoma who have not had prior immune checkpoint inhibitor treatment.[1] This makes the study focused and specific, because it looks at a group that has not yet received that type of immunotherapy.[1]
The Phase 3 safety study includes patients who were already treated with RP1, RP2, or RP3 and are being followed for later safety findings.[2] The listed conditions in this study are metastatic melanoma, advanced solid tumors, hepatocellular carcinoma, and melanoma.[2]
Trial phases and study design
Both studies are interventional, which means the researchers assign treatments or follow treatment-related outcomes in a planned way.[1][2] The uveal melanoma study is Phase 4, and the long-term safety study is Phase 3.[1][2]
Phase 4 studies usually look at a treatment in a broader real-world setting, while Phase 3 studies often confirm safety and effectiveness in larger groups.[1][2] In these trials, the research is centered on later-stage evaluation rather than early testing.[1][2]
Key terms explained
Immune checkpoint inhibitors are cancer drugs that help the immune system attack cancer cells, and the uveal melanoma study compares RP2 against a treatment plan that includes them.[1]
Metastatic means the cancer has spread from the original site to other parts of the body.[1][2]
Herpetic infection means an infection caused by herpes viruses, and the safety study checks whether such infections occur and whether RPx can be found in samples from those lesions.[2]
